Implementing LISA Surfactant in Nigeria

PHASE4CompletedINTERVENTIONAL
Enrollment

349

Participants

Timeline

Start Date

June 25, 2023

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Respiratory Distress SyndromeNeonatal Death
Interventions
DRUG

Surfactant

Laryngoscopy is performed, and BLES® surfactant is administered through BLEScath™ (a thin catheter) into the trachea to a spontaneously breathing preterm infant with respiratory distress syndrome who is being managed on CPAP

Trial Locations (6)

11111

Federal Medical Center Asaba, Asaba

University of Benin Teaching Hospital, Benin City

National Hospital Abuja, Garki

Aminu Kano Teaching Hospital, Zaria

Lagos University Teaching Hospital., Idi-Araba

University of Nigeria Teaching Hospital, Enugu

All Listed Sponsors
collaborator

BLES Biochemicals Inc.

UNKNOWN

lead

Indiana University

OTHER

NCT05714865 - Implementing LISA Surfactant in Nigeria | Biotech Hunter | Biotech Hunter